دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Clearing the radiotherapy backlog: innovation to pave the way
doi : 10.1016/S1470-2045(22)00513-7
Volume 23, Issue 9, September 2022, Page 1109
Adjuvant immunotherapy for renal cell carcinoma
Mehmet Ali NahitSendura
Immune checkpoint inhibition in sarcomas: time to be histology-specific?
AndreaNapolitanoaPaul HHuangbRobin LJonesabChongqiTuc
Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?
ArielleElkriefabcHelenaYuad
What is the best choice of follow-up procedure following resection of lung cancer?
UrsulaNestleabStefanDelormec
Inhibiting TGF-β to increase response rates to chemoradiotherapy in rectal cancer
Paul BRomesserabJ JoshuaSmithc
Customising radiotherapy in stage II breast cancer after primary chemotherapy
YouliaKirovaaPierreLoapa
Ethical considerations for the modification of routine human papillomavirus immunisation schedules
JeffD'SouzaaDavidNderitub
Hitting the sweet spot: optimal use of corticosteroids for immune checkpoint inhibitor side-effects
Andreas MSchmittabLaviniaSpaincdeJamesLarkina
Call for action: expanding global access to hereditary cancer genetic testing
BrittanyBychkovskyabcdHuma QRanabdFolusoAdemuyiwaaeJenniferPlichtaafKarenAndersonagAngélicaNogueira-RodriguesahCesar ASanta-MariaaiLan GCoffmanajCarolMarquezakArunangshuDasalAlphonseTaghianamDiane RKoellerbRenata LSandovalbdnBen HoParkaoDon SDizonap
Thank you and farewell: cancer control and Japan's former Prime Minister Shinzo Abe
YusukeTanakaa
Correction to Lancet Oncol 2022; 23 (Abstracts from the The Lancet Summit: Cancer care in Asia and Latin America Special Issue): S11
Correction to Lancet Oncol 2022; 23 (Abstracts from the The Lancet Summit: Cancer care in Asia and Latin America Special Issue): S29
IAEA expresses concern over situation at Zaporizhzya Nuclear Power Plant
ManjulikaDas
IASLC 2022 World Conference on Lung Cancer
Flávia OliveiraGeraldes
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?
RodrigoDienstmannSaraLonardi
Transforming cancer: behind the scenes at the Crick Institute
CatherineLucas
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
ThomasPowlesMDabPiotrTomczakMD PhDcSe HoonParkMD PhDdBalajiVenugopalMDefThomasFergusonMBBSgStefan NSymeonidesMD PhDhijJaroslavHajekMUDrkProfHowardGurneyMBBSlYen-HwaChangMD PhDmJae LyunLeeMD PhDnNaveedSarwarPhDoAntoineThiery-VuilleminMD PhDpMarineGross-GoupilMD PhDqMauricioMahaveMDrNaomi BHaasMDsPiotrSawryckiMDtJoseph EBurgentsPhDuLeiXuPhDu…MukulGupta
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
ProfReinhardDummerMDa*PaolaQueiroloMDb*Ana MariaAbajo GuijarroPhDcYouyouHuPhDcDaoWangPhDcSergio Jobimde AzevedoMDdProfCarolineRobertMDeProfPaolo AntonioAsciertoMDfVannaChiarion-SileniMDgPaoloPronzatoMDhFrancescoSpagnoloMDhKarmeleMujika EizmendiMDiProfGabriellaLiszkayMDjLuisde la Cruz MerinoMDk†ProfHusseinTawbiMDlâ€
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
NeetaSomaiahMDa†Anthony PConleyMDa†Edwin RogerParraMDb†HeatherLinPhDcBehrangAminiMDdLuisaSolis SotoMDbRuthSalazarMDbCarmeliaBarretoMDbHongleiChenPhDbSwatiGiteMDbCaraHaymakerPhDbElise FNassifMDeChantaleBernatchezPhDfAkashMitraPhDiJohn AndrewLivingstonMDaVinodRaviMDaProfDejka MAraujoMDaProfRobertBenjaminMDa…ProfPatrickHwuMDm
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
ProfShunLuMD PhDa†ProfLinWuMD PhDb†HongJianMDaProfYingChenMDcQimingWangMDdProfJianFangMDeZipingWangMDeProfYanpingHuMDfMeiliSunMDgLiangHanMDhProfLiyunMiaoMDiCuiminDingMDjProfJiuweiCuiMDkProfBaolanLiMD PhDlProfYueyinPanMDmXingyaLiMDnFengYeMDoProfAnwenLiuMDp…ChengliZhangMDs
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial
ProfVirginieWesteelMDaPascalFoucherMDbProfArnaudScherpereelMDcJeanDomasMDdPhilippeGirardMDeProfJeanTrédanielMDfProfMarieWislezMDgPatrickDumontMDhProfElisabethQuoixMDiOlivierRaffyMDjDenisBraunMDkMarcDerollezMDlFrançoisGoupilMDmJacquesHermannMDnEtienneDevinMDoHubertBarbieuxMDpEricPichonMDqDidierDebieuvreMDr…ProfFabriceBarlesiMDagah
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial
TomokoYamazakiPhDaAndrew JGundersonPhDaMirandaGilchristBSacMarkWhitefordMDdMaria XKielyMDdAmandaHaymanMDdDavidO'BrienMDdRehanAhmadMDdJeffrey VManchioMDfNathanielFoxMSaKaylaMcCartyBAaMichaelaPhillipsBAaEvelynBrosnanMDbGinaVaccaroMDbRuiLiPhDbMiklosSimonMDgEricBernsteinMDbMaryMcCormickRNa…Kristina HYoungPhDae
De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study
Sabine Rde WildMDaLindade MunckPhDdJanine MSimonsPhDaeJannekeVerloopPhDdThijsvan DalenPhDfPaula H MElkhuizenPhDgRuud M AHoubenMScbA Elisevan LeeuwenPhDjProfSabine CLinnPhDhProfRuud MPijnappelPhDkProfPhilip M PPoortmansPhDlmLuc J AStrobbePhDnProfJelleWesselingPhDiAdri CVoogdPhDcdoProfLiesbeth JBoersmaPhDb
Health service planning to assess the expected impact of centralising specialist cancer services on travel times, equity, and outcomes: a national population-based modelling study
AjayAggarwalPhDab†LuHanPhDa†Stephanievan der GeestMSccDanielLewisPhDdProfYolandeLievensPhDeProfJosepBorrasPhDfProfDavidJaynePhDgProfRichardSullivanPhDhProfMarcoVarkevisserPhDcProfJanvan der MeulenPhDa
A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study
AndreasKleppePhDacOle-JohanSkredeMScacSeppDe RaedtPhDacTarjei SHveemPhDaHanne AAskautrudPhDaJørn EJacobsenMScaeDavid NChurchDPhilfgProfArildNesbakkenPhDbdjProfNeil AShepherdDMkProfMarcoNovelliPhDalProfRachelKerrPhDhProfKnutLiestølPhDacProfDavid JKerrDSciProfHåvard EDanielsenPhDaci
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview
Eline LGirauda*Kaylee R MFerrierPharmDd*Nienke A GLankheetPhDdIngrid M EDesarMDbNeeltjeSteeghsMDeRypko JBeukemaPhDcProfNielka Pvan ErpPhDaElise JSmoldersPhDaf
CNS prophylaxis for diffuse large B-cell lymphoma
Toby AEyreMDaProfKerry JSavageMDbProfChan YCheahMDcdeProfTarec CEl-GalalyMDfghKatharine LLewisMDcdePamelaMcKayMDiMatthew RWilsonMDjProfAndrew MEvensPhDklSabelaBobilloMDmDiegoVillaMDbMatthew JMaurerDMScnKateCwynarskiPhDoProfAndrés J MFerreriMDp
Te Aho o Te Kahu: weaving equity into national-level cancer control
MichelleMakoMPHaJasonGurneyPhDabcMoahiaGozaMAcMyraRukaMBChBcdNinaScottMBChBcdGaryThompsonMMgtcProfDianaSarfatiPhDa
